Company Overview and News

8
Is it time to bet on O&G?

2018-06-18 theedgemarkets
KUALA LUMPUR: With the stock market, particularly construction counters, roiled by major policy changes under the new Pakatan Harapan administration, the oil and gas (O&G) sector may be ripe for a relook as crude oil prices have been maintained at fairly decent levels.
4456 BRDBF HIPEF 7277 5210 5199

39
Bursa Malaysia up sharply

2018-06-06 thestar.com.my
PETALING JAYA: Snapping two days of losses, the Malaysian stock market closed sharply higher yesterday on renewed buying interest.
PBLOF 6399 1295 5199 5226 4456 4863 6888 TWTR AXXTF MYTEF BSMAF HIPEF 1818

2
High crude oil prices a boon for Hibiscus

2018-05-29 thestar.com.my
“The group now has two assets in different geographies, each delivering positive cashflow against a backdrop of strengthening oil prices,” said Hibiscus managing director Kenneth Pereira .
HIPEF 5199

6
Oil prices at fresh highs

2018-04-24 thestar.com.my
PETALING JAYA: Oil prices continued to climb to a near 3½-year high, crossing the US$75 per barrel mark on expectations of lower supply.
BSMAF HIPEF 1818 5199

9
How long can the oil price rally last?

2018-04-14 thestar.com.my
CRUDE oil prices have held up pretty well over the week. But the question on how long this will last remains.
BRDBF BSMAF HIPEF 5210 1818 5199

32
Brent hits US$71 on US reaction to Syria political unrest

2018-04-13 thestar.com.my
PETALING JAYA: In levels not seen since December 2014, Brent crude oil hit US$71.72 as political tensions rose after US President Donald Trump’s tweet that he would fire missiles at Syria in response to a suspected chemical weapon attack.
1201 RDS.B RDS.A BRDBF XOM RYDBF RDSB RDSA RYDAF HIPEF 5199 5210

10
KL shares plunge by 34 points as market spooked by US-China trade war

2018-04-04 themalaymailonline
Bursa Malaysia experienced heavy selling in late afternoon session on April 4, 2018 amid fears of a trade war between the United States and China. — Reuters file picKUALA LUMPUR, April 4 — Shares in Bursa Malaysia experienced heavy selling in today’s late afternoon session causing the main index to close 1.88 per cent lower, amid fears of a trade war between the United States and China.
PBLOF 1295 BSMAF HIPEF 1818 5199

10
Bursa Malaysia remains negative at mid-afternoon

2018-04-04 themalaymailonline
Bursa Malaysia remained negative at mid-afternoon on April 4, 2018 on weak market sentiment due to a possible full-blown trade war. —Rreuters file picKUALA LUMPUR, April 4 — Bursa Malaysia remained negative at mid-afternoon today on weak market sentiment due to a possible full-blown trade war, after China raised tariffs by up to 25 per cent on selective US food products.
PBLOF 1295 BSMAF HIPEF 1818 5199

10
Bursa Malaysia ends lower on profit-taking

2018-04-03 themalaymailonline
KUALA LUMPUR, April 3 — Bursa Malaysia ended lower today on persistent profit-taking in selected heavyweights and lower-liners, dealers said.
PBLOF 1295 BSMAF HIPEF 1818 5199

10
Bursa Malaysia remains negative at mid-afternoon

2018-04-03 themalaymailonline
At 3.04pm, the FTSE Bursa Malaysia KLCI (FBM KLCI) traded 3.61 points lower at 1,854.74 from yesterday’s 1,858.35. — Picture Ahmad ZamzahuriKUALA LUMPUR, April 3 ― Bursa Malaysia remained negative at mid-afternoon today on continued profit-taking led by selected blue chip stocks, dealers said.
PBLOF 1295 BSMAF HIPEF 1818 5199

10
Bursa Malaysia ends morning session lower

2018-04-03 themalaymailonline
At 12.30pm, the FTSE Bursa Malaysia KLCI (FBM KLCI) stood 3.53 points lower at 1,854.82 from Monday’s 1,858.35. — Picture by Azneal IshakKUALA LUMPUR, April 3 ― Bursa Malaysia ended the morning session lower today on profit-taking on selective heavyweights and lower-liners, and in tracking its regional peers and overnight sell-off on Wall Street, dealers said.
PBLOF 1295 BSMAF HIPEF 1818 5199

10
Bursa Malaysia lower at mid-morning

2018-04-03 themalaymailonline
At 11.01am, the FTSE Bursa Malaysia KLCI (FBM KLCI) were trading at 0.67 of-a-point lower at 1,857.68 from yesterday’s 1,858.35. — Picture by Azneal IshakKUALA LUMPUR, April 3 ― Bursa Malaysia stayed lower at mid-morning today in tracking regional peers following overnight losses on Wall Street, dealers said.
PBLOF 1295 BSMAF HIPEF 1818 5199

6
Hibiscus actively traded in morning trade

2018-04-03 thestar.com.my
KUALA LUMPUR: Hibiscus Petroleum Bhd is among the most traded stocks in early trade on Tuesday following the completion of a 50% stake in North Sabah Enhanced Oil Recovery Production Sharing Contract (PSC).
BSMAF HIPEF 5199 1818

7
Trading ideas: Hibiscus, GFM, WCT, TNB, Datasonic

2018-04-03 thestar.com.my
KUALA LUMPUR: Hibiscus Petroleum Bhd , GFM Services Bhd, WCT holdings Bhd , Tenaga Nasional Bhd (TNB) and Datasonic Group Bhd are among the stocks to watch, according to JF Apex Research.
5216 5347 TNABY TNABF HIPEF 5199

2
Hibiscus completes stake buy

2018-04-02 thestar.com.my
KUALA LUMPUR: Hibiscus Petroleum Bhd has completed its acquisition of 50% participating interest in the 2011 North Sabah Enhanced Oil Recovery Production Sharing Contract (PSC) and the joint operating agreement (JOA) in relation to the PSC.
HIPEF 5199

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

21h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...